Indivior receives settlement approval for antitrust litigation
Indivior
914.50p
16:40 20/12/24
0.11%
1.00p
Pharmaceuticals business Indivior has received final court approval for a landmark settlement in an antitrust multi-district litigation with the direct purchaser class.
FTSE 250
20,450.69
17:14 20/12/24
n/a
n/a
FTSE 350
4,463.29
17:14 20/12/24
n/a
n/a
FTSE All-Share
4,421.11
17:04 20/12/24
n/a
n/a
Pharmaceuticals & Biotechnology
19,761.12
17:14 20/12/24
0.06%
12.71
Indivior said on Thursday that on 27 February, the United States District Court for the Eastern District of Pennsylvania entered an order granting final judgement and order of dismissal approving its direct purchaser class settlement and dismissing direct purchaser class claims.
The FTSE 250-listed group noted that the ruling, which follows a $385.0m settlement agreement in October 2023, now concludes the antitrust multi-district litigation .
As of 0945 GMT, Indivior shares were up 0.99% at 1,736.0p.
Reporting by Iain Gilbert at Sharecast.com